10-Q: United Therapeutics Reports Strong Q2 Growth, Advances Organ Manufacturing Pipeline

United Therapeutics Corporation announced robust second-quarter financial results, fueled by significant growth in Tyvaso DPI sales, while making substantial progress in its innovative organ manufacturing and xenotransplantation programs.

Summary

• Total revenues increased by 12% to $798.6 million for the three months ended June 30, 2025, and by 14% to $1,593.0 million for the six months ended June 30, 2025, compared to the same periods in 2024.
• Net income rose to $309.5 million for the three months and $631.7 million for the six months ended June 30, 2025, up from $278.1 million and $584.7 million, respectively, in 2024.
• Tyvaso DPI sales surged by 22% to $315.2 million for the quarter and 27% to $617.7 million for the six-month period, primarily due to increased patient numbers, including PH-ILD patients, and higher commercial utilization following Medicare Part D benefit redesign.
• Orenitram sales increased by 16% to $123.9 million for the quarter and 15% to $244.6 million for the six-month period, also benefiting from increased quantities sold and Medicare Part D changes.
• The company received FDA clearance for its Investigational New Drug (IND) application for the UKidney product in January 2025, enabling the commencement of the EXPAND clinical trial.
• An IND for the UThymoKidney product (EXTEND study) was submitted to the FDA in July 2025, and an IND for the UHeart product (EXPRESS study) is being prepared for near-term submission.
• Enrollment was completed for the TETON 1 and TETON 2 studies of Nebulized Tyvaso for Idiopathic Pulmonary Fibrosis (IPF) in January 2025 and July 2024, respectively, with topline data expected in September 2025 (TETON 2) and first half of 2026 (TETON 1).
• Enrollment for the ADVANCE OUTCOMES study of Ralinepag for PAH concluded in June 2025, with topline data anticipated in the first half of 2026.
• Miromatrix, a subsidiary focused on manufactured organ alternatives, enrolled the first patient in its Phase 1 miroliver ELAP study in June 2025.
• A $21.7 million impairment charge was recorded for property, plant, and equipment during the three and six months ended June 30, 2025.
• The company accrued an additional $1.5 million through Q2 2025 for the Sandoz litigation, bringing the total accrued liability to $72.6 million, reflecting damages and prejudgment interest.

Sentiment

Score: 8

Explanation: The company demonstrated strong financial performance with significant revenue and net income growth, primarily driven by its key product, Tyvaso DPI. Substantial progress in the high-potential organ manufacturing and xenotransplantation programs, including IND clearances and clinical trial initiations, indicates strong long-term strategic execution. While facing increased competition and ongoing litigation, the overall outlook is positive due to core product strength and innovative pipeline advancements.

Positives

• Strong revenue growth: Total revenues increased by 12% for the quarter and 14% for the six months.
• Key product growth: Tyvaso DPI sales grew 22% for the quarter and 27% for the six months, driven by patient growth and Medicare Part D benefit redesign. Orenitram sales also increased significantly (16% for the quarter, 15% for six months).
• Increased profitability: Operating income increased by 14% for the quarter and 10.5% for the six months. Net income increased by 11% for the quarter and 8% for the six months.
• Robust cash flow from operations: Net cash provided by operating activities increased by 7% to $652.9 million for the six months.
• Significant progress in xenotransplantation: FDA IND clearance for UKidney (EXPAND study) in January 2025, IND submission for UThymoKidney (EXTEND study) in July 2025, and preparation for UHeart IND (EXPRESS study).
• Expansion of DPF facilities: Inaugurated a DPF facility in Virginia in February 2024 and began construction of two additional DPF facilities in Minnesota and Texas to support future growth.
• Pipeline advancements: TETON 1 and TETON 2 studies (IPF) completed enrollment, ADVANCE OUTCOMES study (Ralinepag for PAH) concluded enrollment, and miroliver ELAP (manufactured liver alternative) enrolled its first patient in a Phase 1 study.
• Successful test flight of hydrogen-powered helicopter: Completed what is believed to be the world's first successful test flight of a piloted hydrogen-powered helicopter in March 2025, supporting sustainable organ delivery.
• New credit facility: Entered into a $2.5 billion unsecured revolving credit facility in April 2025, with a zero outstanding balance as of June 30, 2025, enhancing liquidity.
• Share repurchase authorization: Board authorized an additional $1.0 billion share repurchase program in July 2025, signaling confidence and potential shareholder return.

Negatives

• Remodulin sales decline: Remodulin net product sales decreased by 9% for the quarter and 1% for the six months ended June 30, 2025, primarily due to generic competition.
• Increased operating expenses: Total operating expenses increased by 10% for the quarter and 18% for the six months, driven by higher cost of sales, R&D, and SG&A.
• Impairment charge: Recorded a $21.7 million impairment charge on property, plant, and equipment.
• Increased gross-to-net deductions: Rebate agreements with pharmacy benefit managers, effective in the second half of 2024, have increased gross-to-net deductions for Tyvaso DPI, Orenitram, and Nebulized Tyvaso, impacting net revenues.
• Increased cash used in investing activities: Net cash used in investing activities increased significantly by $1,119.9 million for the six months, primarily due to higher purchases of marketable investments and property, plant, and equipment.
• New competition: Liquidia obtained final FDA approval and launched commercial sales of Yutrepia in May/June 2025, which directly competes with Tyvaso DPI and Nebulized Tyvaso. Merck's Winrevair also competes with treprostinil-based products.
• Ongoing litigation: Significant legal proceedings, particularly the Sandoz litigation (accrued $72.6 million liability) and multiple lawsuits with Liquidia, pose financial and operational risks.
• Increased income tax expense: Income tax expense increased to $200.2 million for the six months ended June 30, 2025, from $169.2 million in 2024, with the effective tax rate rising to 24% from 22% due to decreased excess tax benefits from share-based compensation.

Risks

• Heavy reliance on treprostinil-based therapies, with potential for material adverse impact from sales declines due to competition, regulatory changes, or pricing pressures.
• Availability of generic versions of products (Remodulin, potential for Nebulized Tyvaso and Orenitram) and new therapies (Merck's Winrevair, Liquidia's Yutrepia) could negatively impact sales and profits.
• Failure in clinical trials or delays in obtaining regulatory approvals for new products, new indications, or delivery devices, which could lead to significant delays, additional costs, or discontinuation of development efforts.
• Inability to compete successfully with well-established drug companies that possess greater financial, marketing, manufacturing, sales, distribution, and technical resources.
• Commercial success depends on adequate coverage and reimbursement from third-party payers (governmental and private insurers), with risks of reduced reimbursement rates, price caps, and increased rebates due to healthcare reform initiatives like the Inflation Reduction Act.
• Manufacturing strategy exposes the company to significant risks, including reliance on third parties, insufficient internal or third-party manufacturing capacity, supply chain disruptions, aging infrastructure, quality control issues, and the complex, capital-intensive nature of manufactured organ production.
• Reliance on a limited number of distributors (Accredo, CVS Specialty) and sole-source suppliers for pumps, devices, and raw materials, which could lead to supply disruptions.
• Reports of actual or perceived side effects and other adverse effects associated with products could decrease sales or lead to regulatory approval revocations.
• Negative attention from special interest groups regarding animal testing in organ manufacturing programs could impede business operations.
• Inadequate insurance coverage for significant product liability claims.
• Failure to attract and retain key management and qualified scientific and technical personnel.
• Non-compliance with extensive laws and regulations globally, including anti-kickback, false claims, and antitrust statutes, which could result in penalties, fines, or operational restructuring.
• Increased scrutiny of patient assistance programs and the implementation of co-pay accumulator/maximizer programs could limit patient access and product utilization.
• Improper handling of hazardous materials used in research, development, and manufacturing could lead to significant remediation liabilities.
• Cybersecurity incidents and other disruptions impacting networks, systems, or data could result in loss of sensitive information, operational disruption, and reputational damage.
• Intellectual property rights may not effectively deter competitors, and ongoing patent litigation or challenges to patent validity could result in substantial damages or loss of ability to sell products.
• Need for additional financing for unplanned or planned expenditures, with risks of inability to obtain funding on commercially reasonable terms or at all.
• Portfolio of investments is subject to market, interest, operational, and credit risk, potentially leading to declines in value or impairment charges.
• Risks associated with acquisitions, including integration challenges, increased operating costs, and diversion of management attention.
• The price of common stock can be highly volatile due to various factors, including financial results, clinical trial outcomes, competition, litigation, and regulatory changes.
• Conversion to a Delaware Public Benefit Corporation (PBC) requires directors to balance shareholder and stakeholder interests, which may affect decision-making in change of control scenarios and could lead to increased litigation risk.

Future Outlook

The company anticipates near-term revenue growth primarily from continued sales increases of Tyvaso DPI and Orenitram, especially driven by growth in PH-ILD patients and the impact of Medicare Part D benefit redesign, along with modest price increases. Mediumand longer-term revenue growth is expected from new products, new indications for existing products, and new delivery devices. The company plans approximately $710 million in capital expenditures from Q3 2025 through 2027 for new manufacturing facilities, including a Tyvaso DPI facility and DPF facilities for xenotransplantation, which will be funded by cash on hand. While initial DPF facilities are expected to provide commercial supply, additional capital-intensive DPF facilities may be needed to meet future demand for xeno-organ products, with construction staged based on clinical and regulatory progress. The company acknowledges potential material impact on Tyvaso DPI revenues from new competition like Liquidia's Yutrepia if it gains significant market share or causes price erosion, though no material impact has been seen to date.

Management Comments

• "We believe that our current sources of liquidity are sufficient to fund ongoing operations and future business plans as we expect aggregate growth in revenues from our commercial products."
• "We anticipate that revenue growth over the near-term will be driven primarily by: (1) continued growth in sales of Tyvaso DPI; (2) continued growth in the number of PH-ILD patients prescribed Tyvaso DPI and Nebulized Tyvaso; (3) continued growth in the number of patients prescribed Orenitram; and (4) modest price increases for some of our products."
• "We believe that additional revenue growth in the mediumand longer-term will be driven by new products, new indications for existing products, and new devices to deliver our existing products."
• "We anticipate our existing DPF facility in Virginia and the two planned DPF facilities in Minnesota and Texas will provide an initial commercial supply of our xeno-organ products if and when they are approved by the FDA."
• "However, if our xeno-organ products are approved by the FDA, we likely will need to continue building additional DPF facilities to satisfy demand for these products. Additional DPF facilities will be very capital-intensive, but we expect they will be executed in stages, which will enable us to adjust the schedule (and anticipated cost) of construction depending on the progress of our clinical and regulatory activities."
• "While we have not seen a material impact of Yutrepia's launch to date, our Tyvaso DPI net revenues could be materially impacted if Yutrepia gains significant market share or causes material price erosion."

Industry Context

The company operates in the highly competitive biotechnology and pharmaceutical sectors, particularly in the treatment of pulmonary hypertension (PAH) and interstitial lung disease (ILD). It faces competition from over fifteen branded and generic drugs for PAH, including new market entrants like Merck's Winrevair (approved March 2024) and Liquidia's recently approved and launched Yutrepia (May/June 2025), which directly competes with its treprostinil-based products. The company is also a pioneer in organ manufacturing, including xenotransplantation, regenerative medicine, and ex vivo lung perfusion, addressing the critical shortage of transplantable organs. This long-term strategy positions it uniquely in the broader healthcare landscape, aiming to provide solutions for diseases currently incurable by pharmaceutical means. Its efforts in sustainable organ delivery via electric aircraft also align with broader industry trends towards environmental responsibility and logistical innovation.

Comparison to Industry Standards

• PAH Market Competition: The company competes with over fifteen branded and generic drugs for PAH. Specific competitors mentioned include Merck's Winrevair (sotatercept-csrk), approved in March 2024, and Liquidia's Yutrepia, a dry powder treprostinil formulation approved in May 2025 and launched in June 2025.
• IP Receptor Agonists: Ralinepag, the company's once-daily oral prostacyclin receptor agonist, is being developed to compete with Johnson & Johnson's Uptravi (selexipag), a twice-daily IP-receptor agonist. Johnson & Johnson reported global sales of Uptravi exceeding $1.8 billion in 2024, with over $1.5 billion in U.S. sales, reflecting a 14% growth rate over 2023. The company expects ralinepag's once-daily dosing to be a favorable differentiator.
• Organ Manufacturing: The company is a leader in xenotransplantation, with successful human xenotransplants of porcine hearts (UMSOM, January 2022, September 2023) and kidneys (NYU Langone Health, April 2024, November 2024). These procedures, including the first known transplantation of a thymokidney into a human and the longest documented case of a xenotransplanted organ functioning in a human body (61 days for UThymoKidney in brain-dead donor), represent significant advancements in the field.
• Manufactured Organ Alternatives: Miromatrix's miroliver ELAP, a manufactured liver assist product, initiated a Phase 1 human clinical trial in October 2024 and enrolled its first patient in June 2025, marking the first human clinical trial of a manufactured organ alternative.
• Ex Vivo Lung Perfusion (EVLP): The company's Lung Bioengineering Inc. provides the only commercially available centralized EVLP service in the United States using FDA-approved technology (XPS with Steen Solution Perfusate). Over 600 patients have received lung transplants following the use of this service. A premarket approval application for another EVLP technology, CLES, was submitted to the FDA in September 2024.
• Sustainable Organ Delivery: The company's collaboration with BETA Technologies, Inc. and Robinson Helicopter Company for electric vertical take-off and landing aircraft systems for organ delivery is a pioneering effort. This includes the first-ever drone delivery of a human lung for transplant (October 2021) and the world's first successful test flight of a piloted hydrogen-powered helicopter (March 2025).

Corporate Governance

Legal Proceedings

• Sandoz Litigation: A lawsuit filed by Sandoz Inc. and Liquidia PAH, LLC alleging anticompetitive conduct and breach of a patent settlement agreement related to generic Remodulin infusion devices. The court entered a final judgment in favor of Sandoz in November 2024, ordering payment of approximately $61.6 million in damages and $9.0 million in prejudgment interest. All parties have appealed the final judgment, and oral argument is expected this year. An aggregate liability of $72.6 million has been accrued as of June 30, 2025.
• Liquidia Technologies, Inc. Litigation: Multiple ongoing lawsuits including a patent infringement lawsuit filed by United Therapeutics against Liquidia (re: 327 patent expiring Feb 2042) alleging infringement by Yutrepia, with trial in June 2025 and post-trial briefing in early August 2025. A separate trade secret misappropriation case and a new breach of contract case filed by United Therapeutics against Liquidia and a former executive (Dr. Robert Roscigno) in North Carolina state court are ongoing. Liquidia has also filed a patent infringement lawsuit against United Therapeutics alleging Tyvaso DPI infringes U.S. Patent No. 10,898,494 (expires May 2037). United Therapeutics has also filed a patent infringement lawsuit against Liquidia alleging Yutrepia infringes U.S. Patent No. 11,357,782 (expires May 2027).
• FDA Litigation Regarding Yutrepia: United Therapeutics' action against the FDA regarding Liquidia's pursuit of a PH-ILD indication via NDA amendment was voluntarily dismissed. Liquidia's action against the FDA challenging United Therapeutics' exclusivity award was decided in favor of the FDA's award of exclusivity in February 2025. United Therapeutics' cross-claim against the FDA related to the PH-ILD indication was dismissed.
• MSP Recovery Litigation: A class action complaint alleging RICO and state law violations related to charitable contributions to a PAH fund. A magistrate judge recommended dismissal of the complaint with prejudice in March 2024, which the plaintiffs have objected to.
• Litigation with Humana and United Healthcare: Separate lawsuits alleging RICO and state law violations related to charitable contributions to CVC. The U.S. District Court dismissed both complaints in March 2024. Humana and United each filed new lawsuits in Maryland state court in April 2024 with similar allegations, and motions to dismiss are pending.

Stakeholder Impact

• Shareholders: Potential for increased value through share repurchases and long-term growth from pipeline advancements, but also exposure to stock price volatility, litigation risks, and the unique governance structure of a Public Benefit Corporation.
• Patients: Continued access to existing therapies (Tyvaso DPI, Nebulized Tyvaso, Remodulin, Orenitram, Unituxin, Adcirca) and potential for new treatment options for chronic and life-threatening conditions, particularly in PAH, PH-ILD, IPF, PPF, and end-stage organ failure through xenotransplantation and regenerative medicine.
• Employees: Benefits from share-based compensation plans and potential for growth in headcount, but also subject to intense competition for qualified personnel.
• Customers (Distributors): Continued reliance on key distributors (Accredo, CVS Specialty) for product sales and distribution, with potential impacts from rebate agreements and supply chain dynamics.
• Suppliers: Continued reliance on third-party manufacturers and suppliers for drug products, devices, and raw materials, with risks of supply disruptions and cost increases.
• Creditors: Compliance with covenants under the new $2.5 billion credit agreement.
• Regulatory Authorities: Ongoing engagement with the FDA and international counterparts for product approvals, label expansions, and compliance with manufacturing and marketing regulations.

Next Steps

• Launch of RemunityPRO, a new version of the Remunity Pump, later this year.
• Anticipate announcing topline data from the TETON 2 study in September 2025.
• Post-trial briefing in the Liquidia patent infringement lawsuit (re: 327 patent) scheduled to be completed in early August 2025.
• Expect to continue accruing clinical worsening events in the ADVANCE OUTCOMES study through the end of 2025.
• Prepare to submit an IND for a clinical study of the UHeart product (EXPRESS study) in the near term.
• Anticipate announcing topline data from the TETON 1 study during the first half of 2026.
• Release topline data from the ADVANCE OUTCOMES study in the first half of 2026.
• If TETON studies are successful, plan to seek FDA approval to expand Nebulized Tyvaso label to include IPF and PPF, and Tyvaso DPI label to include IPF and PPF (following bridging studies).
• Consider seeking amendments to marketing authorizations for Nebulized Tyvaso in other countries to include IPF and/or PPF indications.
• If ADVANCE OUTCOMES study is successful, plan to develop an oral triple-combination therapy consisting of ralinepag, an endothelin receptor antagonist, and a PDE-5 inhibitor.
• Continue building additional DPF facilities for commercial use of xeno-organ products if approved, with expenditures executed in stages.
• Qualify the Research Triangle Park facility to produce primary commercial supply of ralinepag if approved.
• Monitor and defend against ongoing litigation, including appeals in the Sandoz case and various Liquidia lawsuits.
• Evaluate the impact of the One Big Beautiful Bill Act (OBBBA) on consolidated financial statements.

Key Dates

Recommendation

The company demonstrates strong financial health with significant revenue and net income growth, primarily driven by its flagship product, Tyvaso DPI. Its aggressive investment in the innovative and high-potential organ manufacturing and xenotransplantation programs, evidenced by recent IND clearances and clinical trial initiations, positions it for substantial long-term growth in addressing critical unmet medical needs. While facing increased competition from new market entrants like Liquidia's Yutrepia and ongoing, complex litigation, the company's core product performance, robust cash flow from operations, and strategic pipeline advancements suggest a favorable outlook for investors seeking growth in the biotechnology sector. The recent authorization of a $1.0 billion share repurchase program further signals management's confidence in the company's value.

Keywords

Biotechnology, Pharmaceuticals, Pulmonary Arterial Hypertension, Interstitial Lung Disease, Treprostinil, Tyvaso DPI, Nebulized Tyvaso, Remodulin, Orenitram, Unituxin, Adcirca, Xenotransplantation, Organ Manufacturing, Regenerative Medicine, Clinical Trials, FDA Approval, SEC Filing, Quarterly Report, Drug Development, Rare Diseases, Biologics, Medical Devices, Intellectual Property, Litigation, Financial Results, Biotech Investment